Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights
This study provides compelling evidence for the clinical utility of sMUC5AC as a prognostic biomarker among patients with resected PDA. Future large-scale studies are needed to validate these findings and establish standard thresholds for sMUC5AC integration into clinical practice.
Authors
- Anup Kasi (ORCID: https://orcid.org/0000-0002-4305-5701)
- Ashwini Kumar Esnakula (ORCID: https://orcid.org/0000-0001-6029-0124)
- Upender Manne (ORCID: https://orcid.org/0000-0002-1545-3032)
- Ravi Kumar Paluri (ORCID: https://orcid.org/0000-0002-2317-7082)
- Sravan Jeepalyam
- Lianbo Yu (ORCID: https://orcid.org/0000-0002-2025-2585)
- Amir Sara
- Ashish Manne (ORCID: https://orcid.org/0000-0003-2356-5162)
- Jordan M. Cloyd (ORCID: https://orcid.org/0000-0002-2373-8433)
- Timothy Michael Pawlik (ORCID: https://orcid.org/0000-0002-7994-9870)
- Wancai Yang (ORCID: https://orcid.org/0000-0001-7437-9197)
- Kannan Thanikachalam (ORCID: https://orcid.org/0000-0001-5379-8966)
- Deepak Sherpally (ORCID: https://orcid.org/0000-0002-3330-2721)
- Ankur Sheel (ORCID: https://orcid.org/0000-0003-3408-8445)
- Yonghua Bao
- Susan Tsai
Institutions
- Atrium Health Wake Forest Baptist (US)
- Roswell Park Comprehensive Cancer Center (US)
- New York Medical College (US)
- Stormont Vail Health (US)
- University of Alabama at Birmingham (US)
- The University of Kansas Cancer Center (US)
- The Ohio State University (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.3389/fonc.2025.1544928
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ohio State University
- Pelotonia
- National Cancer Institute